This is from a June 3 press release:
"...Dr. Yancopoulos and Dr. Stahl will assume their new positions effective July 1, 1997.
Separately, Regeneron announced that Ronald M. Lindsay, Ph.D., Vice President, Neurobiology, will leave the Company
effective June 30, 1997 to pursue other interests. ``Ron played an important role in the formation, development, and growth of
Regeneron, particularly in its groundbreaking work in the area of neurotrophic factors. We wish him well in his future pursuits,''
said Dr. Schleifer. "
It appears that the they are about to slowly silent and phase out the neurotrophin project, I don't see this as a good sign. Let's count on the other stuff they have and the P&G thing works out.
cl
p.s. I now have less faith in the nt-3 trial in neuropathies. |
